StockData
Nomad Power Solutions, Inc. logo

Nomad Power Solutions, Inc. (NMAD) company profile

NMADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$2.85−0.15 (-5.00%)

Close on Nov 18, 2026Market cap $45.89MP/E –Yield –

About Nomad Power Solutions

Pharmaceutical Preparations, SIC 2834

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton therapy enterprise focused on discovering, developing, and commercializing cancer therapies. The organization centers its primary pharmaceutical pipeline on inhibitors of protein phosphatase 2A, targeting their capability to augment the effectiveness of chemotherapy, radiation, and immunotherapy treatments. Its principal investigational asset, designated as LB-100, is undergoing evaluation across several clinical trials, including investigations for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. In parallel, through its majority ownership in Liora Technologies Europe Ltd., the company develops electronically controlled proton therapy equipment using proprietary linear accelerator systems for tumor radiation.

The enterprise maintains its principal executive headquarters in Boca Raton, Florida. Its operational reach and development programs encompass clinical and institutional collaborations across the United States and Europe, including partnerships and research activities associated with entities located in the Netherlands and Spain, alongside operations tied to its European proton therapy subsidiary.

Summary of the business section of Nomad Power Solutions's latest annual report, written by StockData.

Company profile

Company

Legal name
Nomad Power Solutions, Inc.
Headquarters
Boca Raton, FL
Address
433 Plaza Real, Suite 275 33432
Phone
(310) 203-2902
Employees
3, Dec 31, 2020
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Weinberg & Company, P.A, Los Angeles, California

Stock & identifiers

Ticker
NMAD
Former tickers
LIXT until Jul 10, 2026
Exchange
Nasdaq
IPO date
Oct 25, 2007
Shares outstanding
16M, Aug 10, 2026
Public float
$1.98M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jun 5, 2023; 1-for-6 reverse, Mar 26, 2021
SEC CIK
1335105
CUSIP
539319301
ISIN
US5393193017
FIGI
BBG000TC15T7
Share class FIGI
BBG001SZV9C2
LEI
5493004HPIB1PBNQ3L69
EIN
20-2903526

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Peter StazzoneChief Financial Officer100,000
Lourdes FelixDirector55,000
Guy Warren PrimusDirector40,000
Michael Andrew HollowayDirector40,000
Jason David SawyerDirector65,000
John Francis TravagliniDirector–
Stuart D. PorterDirector25,000
Yun YenDirector52,632
Rene BernardsDirector25,000
Stephen J. FormanDirector74,804
Regina BrownDirector6,300

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$153.50K$94.46K$562.38K$17–
FY2023$634.57K$669.20K$550.00K$20–
FY2022$315.64K$315.53K$725.74K$43–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 2, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 2, 2026Name changeName changed from LIXTE BIOTECHNOLOGY HOLDINGS, INC. to Nomad Power Solutions, Inc.
Nov 25, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 18, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 21, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 23, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 23, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 24, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 17, 2020ListingRegistration of securities on an exchange (Form 8-A)
Jan 7, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 22, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
May 16, 2007Late filingNotification of late filing
Dec 1, 2006Name changeName changed from SRKP 7 INC to LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Aug 14, 2006Late filingNotification of late filing
Aug 1, 2006Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 7, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?